Clinical implications for cannabinoid use in the rheumatic diseases: Potential for help or harm?

Arthritis and Rheumatism

Volumn 64, Issue 8, 2012, Pages 2417-2425

  Fitzcharles, Mary Ann ^a   McDougall, Jason ^b   Ste Marie, Peter A ^c   Padjen, Ivan ^d  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d KBC Zagreb   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DICHLOROBENZOYL) 5 METHOXY 2 METHYL 3 (2 MORPHOLINOETHYL)INDOLE; AJULEMIC ACID; ANANDAMIDE; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CANNABIS; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DRONABINOL; ENDOCANNABINOID; MORPHINE; MU OPIATE RECEPTOR; NABILONE; NOLADIN ETHER; VIRODHAMINE;

ANALGESIA; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ANXIETY; ARTHRALGIA; ARTHRITIS; BONE METABOLISM; COGNITIVE DEFECT; DEPRESSION; DISORIENTATION; DIZZINESS; DROWSINESS; DRUG DEPENDENCE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; EUPHORIA; FIBROMYALGIA; HALLUCINATION; HUMAN; IMMUNOMODULATION; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; OSTEOARTHRITIS; PERIODIC LIMB MOVEMENT DISORDER; PRIORITY JOURNAL; REM SLEEP; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; SIDE EFFECT; SLEEP; SUICIDAL IDEATION; SYNOVIAL FLUID;

ARTHRALGIA; BONE AND BONES; CANNABINOIDS; COGNITION DISORDERS; DISEASE MANAGEMENT; HUMANS; IMMUNE SYSTEM; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RHEUMATIC DISEASES;

EID: 84864473425     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34522     Document Type: Review

References (74)

1. Kalant H,. Medicinal use of cannabis: history and current status. Pain Res Manag 2001; 6: 80-91.
2. Robson P,. Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf 2011; 10: 675-85.
3. Pertwee RG,. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 2006; 147 Suppl 1: S163-71.
4. Howlett AC,. A short guide to the nomenclature of seven-transmembrane spanning receptors for lipid mediators. Life Sci 2005; 77: 1522-30.
5. Pertwee RG,. Cannabinoid receptors and pain. Prog Neurobiol 2001; 63: 569-611.
6. Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ,. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001; 323: 13-6.
7. Bronstein K, Dhaliwal J, Leider H,. Rates of inappropriate drug use in the chronic pain population: an update. J Pain 2011; 12: P5.
8. Goldenberg DL, Clauw DJ, Fitzcharles MA,. New concepts in pain research and pain management of the rheumatic diseases. Semin Arthritis Rheum 2011; 41: 319-34.
9. Fitzcharles MA, Almahrezi A, Shir Y,. Pain: understanding and challenges for the rheumatologist [review]. Arthritis Rheum 2005; 52: 3685-92.
10. Courvoisier DS, Agoritsas T, Glauser J, Michaud K, Wolfe F, Cantoni E, et al, on behalf of the Swiss Clinical Quality Management Program for Rheumatoid and the National Data Bank for Rheumatic Diseases. Pain as an important predictor of psychosocial health in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 190-6.
11. Greineisen WE, Turner H,. Immunoactive effects of cannabinoids: considerations for the therapeutic use of cannabinoid receptor agonists and antagonists. Int Immunopharmacol 2010; 10: 547-55.
12. Karst M, Wippermann S, Ahrens J,. Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs 2010; 70: 2409-38.
13. 2 receptor agonist GW405833 on rat osteoarthritic knee joint pain. Osteoarthritis Cartilage 2010; 18: 1536-43.
14. Schuelert N, McDougall JJ,. Cannabinoid-mediated antinociception is enhanced in rat osteoarthritic knees. Arthritis Rheum 2008; 58: 145-53.
15. Schuelert N, Johnson MP, Oskins JL, Jassal K, Chambers MG, McDougall JJ,. Local application of the endocannabinoid hydrolysis inhibitor URB597 reduces nociception in spontaneous and chemically induced models of osteoarthritis. Pain 2011; 152: 975-81.
16. Swift W, Gates P, Dillon P,. Survey of Australians using cannabis for medical purposes. Harm Reduct J 2005; 2: 18.
17. Ware MA, Adams H, Guy GW,. The medicinal use of cannabis in the UK: results of a nationwide survey. Int J Clin Pract 2005; 59: 291-5.
18. Howlett AC,. Cannabinoid receptor signaling. Handb Exp Pharmacol 2005: 53-79.
19. Cravatt BF, Lichtman AH,. The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol 2004; 61: 149-60.
20. Mechoulam R, Parker LA, Gallily R,. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 2002; 42: 11-9S.
21. 2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev 2009; 60: 255-66.
22. Croxford JL, Yamamura T,. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? J Neuroimmunol 2005; 166: 3-18.
23. Baker CL, McDougall JJ,. The cannabinomimetic arachidonyl-2- chloroethylamide (ACEA) acts on capsaicin-sensitive TRPV1 receptors but not cannabinoid receptors in rat joints. Br J Pharmacol 2004; 142: 1361-7.
24. Richardson D, Pearson RG, Kurian N, Latif ML, Garle MJ, Barrett DA, et al. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther 2008; 10: R43.
25. McDougall JJ, Bray RC, Sharkey KA,. Morphological and immunohistochemical examination of nerves in normal and injured collateral ligaments of rat, rabbit, and human knee joints. Anat Rec 1997; 248: 29-39.
26. McDougall JJ, Yeung G, Leonard CA, Bray RC,. A role for calcitonin gene-related peptide in rabbit knee joint ligament healing. Can J Physiol Pharmacol 2000; 78: 535-40.
27. Wotherspoon G, Fox A, McIntyre P, Colley S, Bevan S, Winter J,. Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 2005; 135: 235-45.
28. 1 receptor upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol 2001; 415: R5-7.
29. Lim G, Sung B, Ji RR, Mao J,. Upregulation of spinal cannabinoid-1- receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain 2003; 105: 275-83.
30. Scott DA, Wright CE, Angus JA,. Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Pain 2004; 109: 124-31.
31. +-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett 1997; 221: 157-60.
32. Bridges D, Ahmad K, Rice AS,. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol 2001; 133: 586-94.
33. Ulugol A, Karadag HC, Ipci Y, Tamer M, Dokmeci I,. The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats. Neurosci Lett 2004; 371: 167-70.
34. Dogrul A, Gul H, Yildiz O, Bilgin F, Guzeldemir ME,. Cannabinoids blocks tactile allodynia in diabetic mice without attenuation of its antinociceptive effect. Neurosci Lett 2004; 368: 82-6.
35. Castane A, Celerier E, Martin M, Ledent C, Parmentier M, Maldonado R, et al. Development and expression of neuropathic pain in CB1 knockout mice. Neuropharmacology 2006; 50: 111-22.
36. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, et al. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 2007; 10: 870-9.
37. Rieder SA, Chauhan A, Singh U, Nagarkatti M, Nagarkatti P,. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology 2010; 215: 598-605.
38. Klein TW, Newton CA, Friedman H,. Cannabinoids and the immune system. Pain Res Manag 2001; 6: 95-101.
39. Bidinger B, Torres R, Rossetti RG, Brown L, Beltre R, Burstein S, et al. Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes. Clin Immunol 2003; 108: 95-102.
40. Zuardi AW,. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 2008; 30: 271-80.
41. Weiss L, Zeira M, Reich S, Har-Noy M, Mechoulam R, Slavin S, et al. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 2006; 39: 143-51.
42. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 2000; 97: 9561-6.
43. Marquart S, Zerr P, Akhmetshina A, Palumbo K, Reich N, Tomcik M, et al. Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. Arthritis Rheum 2010; 62: 3467-76.
44. Idris AI, Ralston SH,. Cannabinoids and bone: friend or foe? Calcif Tissue Int 2010; 87: 285-97.
45. George KL, Saltman LH, Stein GS, Lian JB, Zurier RB,. Ajulemic acid, a nonpsychoactive cannabinoid acid, suppresses osteoclastogenesis in mononuclear precursor cells and induces apoptosis in mature osteoclast-like cells. J Cell Physiol 2008; 214: 714-20.
46. Schierenbeck T, Riemann D, Berger M, Hornyak M,. Effect of illicit recreational drugs upon sleep: cocaine, ecstasy and marijuana. Sleep Med Rev 2008; 12: 381-9.
47. Bolla KI, Lesage SR, Gamaldo CE, Neubauer DN, Funderburk FR, Cadet JL, et al. Sleep disturbance in heavy marijuana users. Sleep 2008; 31: 901-8.
48. Russo EB, Guy GW, Robson PJ,. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem Biodivers 2007; 4: 1729-43.
49. Russo E, Guy GW,. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006; 66: 234-46.
50. Pugh G Jr, Smith PB, Dombrowski DS, Welch SP,. The role of endogenous opioids in enhancing the antinociception produced by the combination of Δ9-tetrahydrocannabinol and morphine in the spinal cord. J Pharmacol Exp Ther 1996; 279: 608-16.
51. Rios C, Gomes I, Devi LA,. μ opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 2006; 148: 387-95.
52. 1 agonist or antagonist and involves the serotonergic system in rats. Life Sci 2010; 86: 510-7.
53. 9- tetrahydrocannabinol administration. J Pharmacol Exp Ther 2002; 303: 340-6.
54. Ware MA, Gamsa A, Persson J, Fitzcharles MA,. Cannabis for chronic pain: case series and implications for clinicians. Pain Res Manag 2002; 7: 95-9.
55. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS,. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 2006; 45: 50-2.
56. Ware MA, Fitzcharles MA, Joseph L, Shir Y,. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 2010; 110: 604-10.
57. Skrabek RQ, Galimova L, Ethans K, Perry D,. Nabilone for the treatment of pain in fibromyalgia. J Pain 2008; 9: 164-73.
58. Aggarwal SK, Carter GT, Sullivan MD, ZumBrunnen C, Morrill R, Mayer JD,. Characteristics of patients with chronic pain accessing treatment with medical cannabis in Washington State. J Opioid Manag 2009; 5: 257-86.
59. Lynch ME, Campbell F,. Cannabinoids for treatment of chronic non-cancer pain: a systematic review of randomized trials. Br J Clin Pharmacol 2011; 72: 735-44.
60. Schley M, Legler A, Skopp G, Schmelz M, Konrad C, Rukwied R,. Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. Curr Med Res Opin 2006; 22: 1269-76.
61. Martin-Sanchez E, Furukawa TA, Taylor J, Martin JL,. Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med 2009; 10: 1353-68.
62. Fiz J, Duran M, Capella D, Carbonell J, Farre M,. Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. PLoS One 2011; 6: e18440.
63. Wang T, Collet JP, Shapiro S, Ware MA,. Adverse effects of medical cannabinoids: a systematic review. CMAJ 2008; 178: 1669-78.
64. Kalant H,. Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 849-63.
65. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G,. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study [published errata appears in BMJ 2002;325:435.1]. BMJ 2002; 325: 1199.
66. Nordstrom BR, Levin FR,. Treatment of cannabis use disorders: a review of the literature. Am J Addict 2007; 16: 331-42.
67. Budney AJ, Moore BA, Vandrey RG, Hughes JR,. The time course and significance of cannabis withdrawal. J Abnorm Psychol 2003; 112: 393-402.
68. Schoedel KA, Chen N, Hillard A, White L, Stott C, Russo E, et al. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabixomol oromucosal spray in subjects with a history of recreational cannabis use. Hum Psychopharmacol 2011; 26: 224-36.
69. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS,. Validity of self-reported drug use in chronic pain patients. Clin J Pain 1999; 15: 184-91.
70. Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD,. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain 2007; 8: 573-82.
71. Taylor DR, Fergusson DM, Milne BJ, Horwood LJ, Moffitt TE, Sears MR, et al. A longitudinal study of the effects of tobacco and cannabis exposure on lung function in young adults. Addiction 2002; 97: 1055-61.
72. Tashkin DP, Shapiro BJ, Lee YE, Harper CE,. Subacute effects of heavy marihuana smoking on pulmonary function in healthy men. N Engl J Med 1976; 294: 125-9.
73. Thomson WM, Poulton R, Broadbent JM, Moffitt TE, Caspi A, Beck JD, et al. Cannabis smoking and periodontal disease among young adults. JAMA 2008; 299: 525-31.
74. Zhang ZF, Morgenstern H, Spitz MR, Tashkin DP, Yu GP, Marshall JR, et al. Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev 1999; 8: 1071-8.